Questions around this news
What types of cardiovascular solutions does the company offer?
The release describes clinical, population health and biopharma solutions intended to support cardiovascular disease prevention, detection and management. It says the company currently offers two clinical solutions, Epi+Gen CHD and PrecisionCHD. The release does not provide further details about the population health or biopharma offerings.
How does the company’s cardiovascular platform work?
According to the release, the platform combines genetic and epigenetic biomarkers with analytics powered by artificial intelligence. It uses blood-based testing to provide personalized cardiovascular insights, with the broader aim of supporting prevention, detection and management of cardiovascular disease.
What role do genetics and epigenetics play in cardiovascular risk assessment?
The release says the company’s approach integrates genetic and epigenetic biomarkers and applies AI-driven analytics to blood-based testing. It presents this combination as a way to provide personalized cardiovascular insights and help identify risk earlier, but does not describe specific biomarkers, test procedures or clinical performance results.
- Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies.
- Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care.
- This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes.
Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights the urgent need for more effective tools that can identify risk earlier and guide personalized intervention strategies. Cardio Diagnostics Holdings (NASDAQ: CDIO) is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial intelligence (“AI”), epigenetics and genetics to improve cardiovascular disease prevention, detection and management.
The company’s platform is built around the integration of genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing. Cardio Diagnostics currently offers two clinical solutions, Epi+Gen CHD(TM) and PrecisionCHD(TM), as well as a…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Cardio Diagnostics Holdings
- Ticker
- NASDAQ: CDIO
- Announcement
- Product
Key figures
- Estimated preventable U.S. cardiovascular disease cases
- 80%
